

# Competitor Analysis: CXCR and CXCL Agonists and Antagonists

<https://marketpublishers.com/r/C485B30D368EN.html>

Date: November 2009

Pages: 30

Price: US\$ 345.00 (Single User License)

ID: C485B30D368EN

## Abstracts

### Product description

The present Competitive Intelligence Report about CXCR agonists and CXCR/CXCL antagonists provides a competitor evaluation in the field of chemokine receptor CXCR or its ligands CXCL targeting molecules for tissue regeneration or treatment of cancer and inflammatory diseases of lung, skin or colon as of November 2009. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Chemokines, or chemotactic cytokines, and their receptors have been discovered as essential and selective mediators in leukocyte migration to inflammatory sites and to secondary lymphoid organs. Besides their functions in the immune system, they also play a critical role in tumor initiation, promotion and progression. There are four subgroups of chemokines. The CXC or alpha subgroup is one of the four and can be further subdivided in the ELR(+) and ELR(-) chemokines. Members that contain the ELR motif bind to CXC chemokine receptor 2 (CXCR2) and are angiogenic. In contrast, most of the CXC chemokines without ELR motif bind to CXCR3 and are angiostatic. An exception is the angiogenic ELR(-)CXC chemokine stromal cell-derived factor-1 (CXCL12/SDF-1), which binds to CXCR4 and CXCR7 and is implicated in tumor metastasis.

The CXC receptors and their ligands are promising targets for drug development. The

first approved and marketed drug is plerixafor (AMD3100), a small molecule inhibitor of the CXCR-4/SDF-1 axis, used for stem cell mobilization. CXCR1 and CXCR2 are believed to be crucially involved in the direct migration and activation of leukocytes. Their ligands are supposed to play a key role in several inflammatory diseases and this makes them and their receptors attractive therapeutic targets for inflammatory diseases such as COPD, asthma, psoriasis, ulcerative colitis and rheumatoid arthritis.

The report includes a compilation of current active projects in research and development of molecules targeting chemokine receptor CXCR or its ligands CXCL. In addition, the report lists company-specific R&D pipelines of CXCR and CXCL targeting small molecules, antibodies, proteins, peptides, RNA and cells. Competitor projects are listed in a tabular format providing information on:

Drug Codes,

Target / Mechanism of Action,

Class of Compound,

Company,

Product Category,

Indication,

R&D Stage and

additional comments with a hyperlink leading to the source of information.

## **Index**

CXCR1/2 Antagonists

CXCR3 and CXCL10/IP-10 Antagonists

CXCR4/7 (SDF-1R) Agonists

CXCR4/7 and CXCL12 ((SDF-1) Antagonists

CXCR5 and CXCL13 Antagonists

CXCR6 and CXCL16 Antagonists

Dual CCR5 and CXCR4 Antagonists

Pan-CXCL Inhibitors

Corporate CXCR and CXCL Agonist and Antagonist R&D Pipelines

About La Merie

## **Corporate CXCR and CXCL Agonist and Antagonist R&D Pipelines**

Abbott

Amgen

Ascent Therapeutics

AstraZeneca

Bioheart

Biokine Therapeutics

Bristol-Myers Squibb

ChemoCentryx

Domp?

DRAIS Pharmaceuticals

Genzyme

GlaxoSmithKline

Juventas Therapeutics

Kureha

Northwest Biotherapeutics

NovImmune

Noxxon Pharmaceuticals

Pacgen Pharmaceuticals

PepScan Therapeutics

Polyphor

Provasculon

Samaritan Pharmaceuticals

Schering-Plough (now Merck & Co)

TaiGen Biotechnologies

Teva Pharmaceutical Industries (CoGenesys)

UCB

Unibioscreen

Viron Therapeutics

## **About Competitor Analysis Series**

The Competitor Analysis Series delivers **NO-FRILLS** , but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies **at low prices**. The information is provided in a tabular format and fully referenced. Competitor analysis reports can be purchased as individual products or obtained by subscribing to **R&D Pipeline News**. R&D Pipeline News is published weekly 50-times a year and each issue contains at least two competitor evaluations.

## I would like to order

Product name: Competitor Analysis: CXCR and CXCL Agonists and Antagonists

Product link: <https://marketpublishers.com/r/C485B30D368EN.html>

Price: US\$ 345.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C485B30D368EN.html>